What guidance did Day One's management provide for the next earnings period?

What were the key takeaways from Day One’s earnings call?

What is the revenue and EPS growth rate for Day One year over year?

What were the key takeaways from Day One's earnings call?

Did Day One beat or miss consensus estimates last quarter?

What does Day One do and what are its main business segments?

What is Day One's latest dividend and current dividend yield?

What is the market's earnings forecast for Day One next quarter?

- **OJEMDA Dominance**: 172% YoY revenue growth ($155.4M in 2025) and 180% prescription growth highlight OJEMDA's rapid adoption in pLGG.
- **3-Year Data Strength**: 53% ORR and 19.4-month median response duration validate OJEMDA's durability and safety, positioning it for front-line trials.
- **Pipeline Expansion**: Emi-Le (ACC) shows promise for accelerated approval, while DAY301 advances in PTK7-expressing cancers.
- **Financial Fortitude**: $441M cash position and scalable model support 2026 guidance of $225-250M OJEMDA revenue.

**【CEO Summary Section】**
- Day One Biopharmaceuticals reported $155.4 million in net product revenue for 2025, up 172% year-over-year, driven by OJEMDA's launch in pediatric low-grade glioma (pLGG). Q4 revenue reached $52.8 million, a 37% sequential increase.
- OJEMDA achieved 4,600 total prescriptions in 2025, up 180% from 2024, with 1,300 prescriptions in Q4 despite seasonal impacts.
- 3-year FIREFLY-1 data showed durable responses (53% ORR, median 19.4 months) and manageable safety profile, supporting OJEMDA as a standard of care in second-line pLGG.
- 2026 OJEMDA net product revenue guidance reiterates $225 million to $250 million, reflecting confidence in growth and persistence optimization.

**【CFO Financial Commentary】**
- Full-year 2025 gross product revenue exceeded combined cost of sales and SG&A, highlighting scalability of operating model.
- Cash position of $441 million at year-end (excluding Mersana acquisition) supports pipeline advancement and commercial growth.
- Gross to net rate remained stable at 12-15%, with disciplined channel management and 2-4 weeks of days on hand.
- Operating expenses decreased 17% year-over-year to $286 million, driven by reduced one-time costs.

**【Q&A Key Highlights】**
- **OJEMDA Persistency**: Median duration of therapy trends at 19 months; focus on improving persistency through dose adjustment education, patient support programs, and targeting earlier-line relapsed/refractory patients.
- **Emi-Le (ACC Program)**: Mid-2026 data expected to support accelerated regulatory path; Phase I signals antitumor activity and manageable safety profile in aggressive ACC, a rare disease with no approved therapies.
- **DAY301 Development**: Early clinical activity observed in PTK7-expressing cancers; Phase I dose escalation ongoing with potential expansion into additional indications.
- **Pipeline Strategy**: Emphasis on high-impact, differentiated programs with clear clinical need and regulatory pathways, exemplified by Mersana acquisition.

Day One Biopharmaceuticals, Inc.(DAWN)-20260225-2025 Q4 Earnings call transcript

- **Revenue Growth Accelerates**: Q3 net product revenue up 15% QoQ to $38.5 million, with full year guidance raised to $145-150 million.
- **Clinical Data Drives Adoption**: 2-year FIREFLY-1 data boosts new patient starts, while 3-year data to highlight long-term outcomes at SNO.
- **Financial Strength**: Gross to net at 15%, cash reserves of $451.6 million, and 9% YoY expense decline reflect operational discipline.
- **Pipeline Momentum**: OJEMDA poised for European launch, FIREFLY-2 on track for frontline trial completion, and DAY301 advancing in Phase I.

**【CEO Summary Section】**
- Q3 2025 net product revenue reached $38.5 million, a 15% quarter-over-quarter increase, driven by new patient starts and treatment persistence.
- 2-year FIREFLY-1 data demonstrated reversible growth velocity delays and a median duration of response of 18 months, enhancing physician confidence.
- Full year 2025 revenue guidance updated to $145 million to $150 million, reflecting strong momentum and double-digit sequential growth expectations.
- Pipeline advancements include Ipsen's anticipated EMA approval for OJEMDA in Europe and the Phase III FIREFLY-2 trial on track for enrollment completion in H1 2026.

**【CFO Financial Commentary】**
- Q3 net product revenue of $38.5 million exceeded cost of sales and SG&A, marking a milestone in scalability.
- Total operating expenses decreased 9% YoY to $59.6 million, with disciplined cost management.
- Gross to net rate at 15% for Q3, elevated due to a July price increase impacting Medicaid rebates.
- Cash reserves of $451.6 million support ongoing commercial and pipeline investments.

**【Q&A Highlights】**
- **Treatment Duration & Persistence**: EAP patients showed a median 20-month treatment duration, with 75% continuing beyond 24 months. Commercial patients' persistence data is maturing but aligns with expectations.
- **3-Year FIREFLY-1 Data**: Focus on time to next treatment and tumor rebound post-therapy; 3-year data to be presented at SNO, highlighting long-term safety and efficacy.
- **Pipeline Updates**: DAY301 Phase Ia trial progressing with no significant safety concerns; FIREFLY-2 trial design maintains primary endpoints despite crossover flexibility.
- **Payer Access**: 90%+ first-fill approval rate supports rapid patient access, though off-label use dynamics remain physician-driven.

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript

- **Revenue Milestone**: Q2 2025 net revenue of $33.6M (+10% QoQ), surpassing 1,000 scripts for the first time.
- **Guidance Confidence**: Full-year 2025 target of $140-150M reflects 150% YoY growth, driven by new patient starts and 2-year efficacy data.
- **Payer Strength**: 95% of patients covered by insurance, minimizing financial barriers.
- **Pipeline Momentum**: DAY301 ADC in Phase I, FIREFLY-2 trial on track, and $453M cash to fuel growth.
- **Strategic Focus**: Europe expansion via Ipsen, AI-driven commercial optimization, and disciplined cost management.

**【CEO Opening Remarks】**
- OJEMDA achieved $113.1M in cumulative net revenue over 12 months, surpassing expectations.
- Q2 2025 net product revenue: $33.6M (10% QoQ growth), with >1,000 scripts for the first time.
- Full-year 2025 guidance: $140-150M net revenue, driven by new patient starts and persistence.
- Strategic priorities: Expand OJEMDA in Europe via Ipsen's MAA filing, advance DAY301 ADC, and optimize portfolio.

**【CFO Financial Commentary】**
- Q2 2025: $33.6M net product revenue, $64.1M year-to-date, $113.1M trailing 12-months.
- Guidance assumptions: 150% YoY growth, 12-15% gross-to-net, stable channel stock (2-4 weeks).
- Cost control: $68.9M Q2 expenses (-5% QoQ), $453M cash balance, no debt.

**【Commercial Update】**
- 15% QoQ script growth, 95% payer coverage, <5% free drug utilization.
- 60%+ accounts prescribing >1 patient, 20%+ accounts >5 patients.
- ASCO 2025 data on 2-year growth velocity recovery and rash management drove Q2 script ramp-up.
- 3-year follow-up data expected Q4 2025 to further validate long-term efficacy.

**【Pipeline Progress】**
- DAY301 ADC: Phase Ia dose escalation ongoing, targeting PTK7 in solid tumors.
- FIREFLY-2 frontline trial: On track for 2026 enrollment completion.
- VRK1 program discontinued to refocus resources on high-priority assets.

**【Q&A Highlights】**
- Growth drivers: New patient starts (+15% QoQ) and 2-year data-driven persistence.
- ASCO 2025 rash management data reduced dropout risk, supporting 2-year treatment intent.
- DAY301: Phase I safety/tolerability data expected H2 2025, benchmarking against PTK7 competitors.
- 3-year data expected to reinforce OJEMDA as standard of care in relapsed/refractory pLGG.

Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Growth**: OJEMDA net revenue up 11% QoQ to $30.5M, driven by 16% script growth and 2,500+ total prescriptions.
- **Pipeline Momentum**: FIREFLY-2 on track for H1 2026 enrollment; DAY301 advancing in adult solid tumors with PTK7 targeting.
- **Financial Strength**: $473M cash balance, 4% QoQ expense decline, and stable gross-to-net rate support long-term growth.
- **Strategic Focus**: Establish OJEMDA as 2nd-line standard, deepen prescriber adoption, and evaluate high-impact portfolio additions.

**【CEO Summary Section】**
- Q1 2025 net product revenue for OJEMDA reached $30.5 million, up 11% QoQ, driven by 16% script growth to over 900 quarterly scripts.
- OJEMDA adoption continues in relapsed/refractory pLGG, with 2,500+ total prescriptions since launch and high patient retention rates.
- Pipeline progress: FIREFLY-2 trial on track for full enrollment in H1 2026; DAY301 Phase Ia dose escalation ongoing across adult solid tumors.
- 2025 priorities: Establish OJEMDA as 2nd-line standard, advance clinical pipeline, and evaluate strategic portfolio expansion.

**【CFO Financial Commentary】**
- Q1 2025 operating expenses (excluding cost of sales) were $68.9 million, down 4% QoQ (excluding one-time $20M charge), reflecting disciplined cost management.
- Gross-to-net rate remained stable at ~12-15%, with $473 million cash balance and no debt, providing financial flexibility.
- No immediate financing needs projected, with focus on strategic investments in growth and clinical development.

**【Q&A Key Takeaways】**
- **Patient Duration**: OJEMDA showing consistent retention rates similar to FIREFLY-1 data, with April 2025 marking strongest month for new patient starts.
- **Market Penetration**: 100% of priority 1 accounts have prescribed OJEMDA post-approval; focus shifting to deepening usage in current prescribers.
- **Pipeline Updates**: DAY301 targeting PTK7+ solid tumors; FIREFLY-2 expected to drive frontline pLGG expansion.
- **Business Development**: Actively evaluating high-bar opportunities to expand clinical portfolio, with no immediate asset acquisition plans.

Day One Biopharmaceuticals (DAWN)-6 May 25-2025 Q1 Earnings call transcript

- **OJEMDA Commercial Success**: $57M annual revenue in first 8 months, Q4 2024 sales up 44% to $29M. 1,600+ prescriptions and 280 active patients highlight strong adoption. 
- **Pipeline Momentum**: DAY301 Phase Ia clearing 1st dose cohort; FIREFLY-2 trial on track for H1 2026 enrollment. 
- **Financial Strength**: $531M cash balance supports growth without external financing. CMS pediatric exclusivity reduces gross to net to ~12-15%. 
- **2025 Focus**: Expand OJEMDA prescriber depth, advance clinical trials, and pursue strategic acquisitions.

**【CEO Summary Section】**
- OJEMDA FDA approved for relapsed/refractory pediatric low-grade glioma (pLGG) in April 2024, generating $57M in net product revenue for the year (8 months of sales). Q4 2024 revenue: $29M (44% QoQ growth). 
- 1,600+ total prescriptions by end-2024, with 280 active patients on therapy. New patient starts grew double-digit QoQ. 
- 2025 priorities: 1) Expand OJEMDA prescriber base and patient access; 2) Enroll FIREFLY-2 frontline pLGG trial (targeting H1 2026 completion); 3) Acquire/diligence new pipeline assets. 
- $531M cash balance at year-end, enabling capital allocation for growth without external financing.

**【CFO Financial Commentary】**
- 2024 total revenue: $131.2M (includes $57.2M OJEMDA net sales + $73.9M Ipsen license revenue). 
- Q4 2024 net product revenue: $29M (44% QoQ growth). FY24 gross to net improved 600bps to 17.1% due to CMS pediatric exclusivity designation. 
- Operating expenses: $343.2M (2023: $206.1M), driven by OJEMDA launch costs and R&D investment (e.g., $20M DAY301 in-license fee). 
- 2025 named patient program revenue eliminated ($3M/yr), replaced by Ipsen-managed access programs.

**【Q&A Highlights】**
1. **OJEMDA Growth Outlook**: 
- 2025 focus on expanding prescriber depth (Priority 1-3 accounts) and establishing 2nd-line use. Anticipate steady, linear patient start growth (~double-digit QoQ). 
- CMS pediatric exclusivity reduces gross to net to ~12-15%, supporting margin expansion. 
- Channel inventory stable at 2-4 weeks, no material stocking impact in Q4. 

2. **Pipeline Updates**: 
- DAY301 (PTK7 ADC): Phase Ia dose escalation clearing 1st cohort, now enrolling 2nd. Differentiated by exatecan payload and 8:1 DAR ratio. Potential 1st-in-class ADC for PTK7. 
- FIREFLY-2: 110+ global sites open, targeting H1 2026 enrollment completion. 

3. **Strategic Priorities**: 
- Maintain $500M+ cash position to fund internal growth and external opportunities. 
- Focus on acquiring first/best-in-class assets in pediatric and adult oncology. 
- Leverage Ipsen partnership to expand OJEMDA ex-US access (pending regulatory approvals).

Actual	-5.04	-0.33	-0.345	-0.48	-0.6	-0.53	-0.56	-0.59	-0.61	-0.54	-0.63	-0.72	-0.05	0.38	-0.63	-0.35	-0.29	-0.19	-0.21
Forecast	-0.315	-0.2806	-0.35	-0.385	-0.4875	-0.5226	-0.5527	-0.593	-0.6143	-0.5857	-0.5744	-0.6631	-0.7508	-0.3156	-0.3625	-0.4379	-0.3565	-0.2969	-0.1489
Surprise	-1500.00%	-17.61%	+1.43%	-24.68%	-23.08%	-1.42%	-1.32%	+0.51%	+0.70%	+7.80%	-9.68%	-8.58%	+93.34%	+220.41%	-73.79%	+20.07%	+18.65%	+36.01%	-41.03%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	8.19M	93.76M	29.20M	30.76M	33.91M	39.80M	53.71M
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	1.03M	28.48M	27.83M	30.27M	34.93M	37.82M	49.85M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+698.25%	+229.17%	+4.92%	+1.63%	-2.93%	+5.21%	+7.75%

DAWN

DAWN fundamentals

DAWN Q4 2025 Earnings

Earnings Call

You can ask Aime

DAWN

DAWN fundamentals

DAWN Q4 2025 Earnings

Earnings Call

DAWN Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

DAWN Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

DAWN Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

DAWN Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

DAWN Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

You can ask Aime